Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermabond Advanced is a topical skin adhesive composed of a 2-octyl cyanoacrylate monomer, developed and marketed by Ethicon, a subsidiary of Johnson & Johnson. It is indicated for the topical closure of easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Upon contact with moisture on the skin surface, the liquid monomer polymerizes into a strong, flexible film that holds the wound edges together. This film also acts as a microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for surgical site infections. The "Advanced" formulation is specifically designed for a single-layer application, providing a balance of strength and flexibility while improving drying time and ease of use for clinicians compared to multi-layer predecessors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-octyl cyanoacrylate (Ethicon).